The efficacy of a muramidase-released protein (MRP) and extracellular factor (EF) 
Zutphen, The Netherlands STREPTOCOCCAL meningitis, polyserositis and polyarthritis, is a severe, often fatal disease ofyoung pigs at weaning, and is usually caused by Streptococcus suis serotype 2 (Vecht and others 1985 , Higgins and others 1992 , Reams and others 1994 . S suis strains can be differentiated by serotype on the basis of their capsular polysaccharides. At present, 35 serotypes are known (Perch and others 1983 , Gottschalk and others 1989 Higgins and others 1995) . The virulence of most serotypes is unclear. Strains ofserotypes 2 and 1 are considered to be the most virulent serotypes, but strains of some other serotypes, such as 7, 9 and 14 have also been associated with disease (Sihovenen and others 1988, others 1995, MacLennan and others 1996) .
The economic impact of S suis infections on the pig industry is substantial (Chengappa and others 1990) , and the prophylactic use of antibiotics in food and drinking water has so far been unsuccessful in controlling the disease. Furthermore, antibiotics are becoming less effective because of an increase in resistance among S suis isolates and their use is unpopular because of the public awareness of antimicrobial residues (Aarestrup and others 1998) .
Little is known about the protective antigens of S suis. Whole-cell vaccines with live avirulent or killed virulent S suis serotype 2 cells protected pigs against challenge with a strain of a homologous serotype (Holt and others 1988 , Busque and others 1997 . However, vaccination with whole cells did not induce protection against challenge with a strain of a heterologous serotype (Kebede and others 1990 ). Jacobs and others (1996) showed that a vaccine based on the purified 54 kDa suilysin protected against a homologous challenge, but the absence of this haemolysin from a substantial number of isolates obtained from diseased pigs limits the usefulness of this vaccine (Segers and others 1998) .
In previous work, the authors identified two proteins, the 136 kDa muramidase-released protein (MRP) and the 110 kDa extracellular factor protein (EF), as markers of virulent S suis serotype 1 and 2 strains (Vecht and others 1991) . The MRP iS a membrane-associated protein and EF is an extracellular protein. Both are transported across the bacterial membrane and are major antigens recognised by convalescent sera of infected pigs (Vecht and others 1991) . This paper describes the results of studies of the efficacy of MRP and EF vaccines in preventing infection and disease in pigs challenged with a homologous or a heterologous S suis serotype 2 strain (MRP+EF+), in comparison with the protective capacity of a vaccine containing formalin-killed bacterin of S suis serotype 2 (MRP+EF+).
MATERIALS AND METHODS

Bacterial strains
Strains 4005 (3) and 3881 (10) ofSsuis serotype 2, both belonging to the phenotype MRP+EF+, were used. Both strains were field isolates, isolated from pigs suffering from meningitis and were virulent for newborn germ-free pigs (Vecht and others 1992 (Bokhout and others 1981) .
For the vaccinations with the AH adjuvant, 1 25 mg metallic aluminium was used per dose, according to the manufacturer's instructions. The antigens and AH were stirred for four hours at 4°C. To control adsorption, 1 ml of the mixture was centrifuged in an Eppendorf centrifuge at 10,000 rpm for three minutes, and the supernatants were analysed for the absence of the antigens either by MRP and EF DAS ELISA (Vecht and others 1993) or spectrophotometrically by using an Ultrospec 3000 spectrophotometer (Pharmacia Biotech) at wavelengths of 250 to 650 nm.
For the preparation of the placebo-vaccines the antigen solutions were replaced by a physiological saline solution.
Vaccination
Fifty-five three-week-old pigs, crossbreeds of Yorkshire and Dutch landrace, were obtained from the specified pathogenfree herd of the ID-Lelystad for two experiments. In both experiments the pigs were alloted to six treatment groups each consisting of four or five pigs. The pigs were separated and housed in boxes at the animal facilities of the ID-Lelystad.
Priming vaccinations were given at the age of three weeks.
Each dose contained 50 jtg MRP, 50 jig EF or 1 x 109 formalinkilled whole cells, either separately or in combination, and they were administered intramuscularly, divided over two injection sites, in both upper hind legs. Three weeks later the pigs were boosted intramuscularly in the neck with the same dose of the vaccines without adjuvants.
Challenge
Two weeks after the second vaccination, the pigs were challenged intravenously in the ear vein with 1 x 107 cfu of the homologous S suis serotype 2 strain 4005 (experiment 1) or the heterologous S suis serotype 2 strain 3881 (experiment 2). The inocula were prepared as described by Vecht and others (1992) . The pigs were monitored twice daily for the following clinical signs of disease: fever, disorders of the nervous system, lameness, inappetence and depression. Blood samples were taken once a week before the challenge and three times a week after the challenge to monitor the immune response. White blood cells were counted with a semi-cell blood counter (Sysmex, model F 800; Charles Goffin Medical Systems). The number of neutrophils was calculated after a differential count of Giemsa-stained blood smears. For animal welfare reasons, pigs that were moribund or showed nervous signs were killed by an intravenous injection of pentobarbiturate, exsanguinated and examined postmortem.
Tissue specimens taken from the central nervous system (CNS), serosae, and joints were examined bacteriologically and histologically as described byVecht and others (1992) (Table 3 ). In contrast, the pigs vaccinated with MRP+EF/WO, bacterin/wo and MRP+EF+bac-terin/wo had significantly (P<0.05) fewer lesions, and bacteria were isolated from the lesion sites less frequently.
Lesions were observed at the injection site in the pigs of all groups, except for those vaccinated with the AH-formulated placebo vaccine. They ranged in severity from being less than 1 cm3 in size and involving connective tissue only, to being more than 1 cm3, with necrosis, microabscesses or granulomas (Table 3) Kebede and others (1990) .
wo adjuvant was superior to AH adjuvant in its capacity to stimulate an immune response after vaccination with MRP and EF and to confer protection against challenge with virulent S suis serotype 2 strains. Similarly, Ripley (1983) showed that an oil-based adjuvant produced a significant antibody response with killed bacterins, whereas only a transient increase in antibodies was observed after vaccination with an AH-formulated vaccine. However, it appeared that both wo and AH adjuvants caused serious lesions at the injection sites, and a suitable alternative adjuvant or a refinement of wo is therefore desirable. Holt and others (1990) found that a vaccine containing bacterin without an adjuvant protected as well as bacterin formulated either with Freund's incomplete adjuvant or with aluminium hydroxide gel as an adjuvant. However, the same experiments showed that the protective response to bacterin was stimulated when the size of the inoculum was increased from 1010 to 1011 killed organisms. In this study, the bacterin contained only 109 killed cells, and a strong potentiating adjuvant like wo seemed to be necessary to obtain protection.
Whole-cell vaccines are probably serotype-specific, because protection was achieved only against a strain of a homologous serotype, and the vaccines failed to protect against other serotypes (Kebede and others 1990, Foster and others 1994) . Subunit vaccines based on proteins conserved among serotypes may be more useful in veterinary practice if they protect against challenge with strains of heterologous serotypes. Jacobs and others ( 1996) suggested that suilysin, a thiol-activated haemolysin from S suis serotype 2, could be such a cross-protection factor. Vaccination challenge experiments in pigs indicated that this vaccine protected against challenge with a homologous serotype. However, the haemolysin is absent from quite a number of strains of S suis isolated from diseased pigs in the field. This implies that other vaccine components will be necessary to provide protection against all field strains (Jacobs and others 1996, Segers and others 1998). A 52 kDa immunoglobulin-binding protein which has recently been shown to be identical to a 60 kDa heat-shock protein that is produced by various serotypes, could be another candidate for a subunit vaccine (Serhir and others 1993 , Benkirane and others 1997 . The protective value of this protein has not been tested.
In Europe, the USA and Australia, most of the S suis serotype 2 strains isolated from diseased pigs produce MRP and EF (Mwaniki and others 1994 , Galina and others 1996 , Wisselink and others 2000 . In these countries an MRP+EF vaccine could therefore be of great value. However, most of the S suis serotype 2 strains isolated from diseased pigs in Canada appeared to be MRP and EF negative (Gottschalk and others 1998) . Apparently, Canadian strains differ from strains isolated in other countries. The proteins MRP and/or EF are not only produced by serotype 2 strains. High percentages of European S suis serotype 1, 1/2 and 14 strains, isolated from tissues associated with S suis infections such as brain, serosa, joint, heart and other organs of diseased pigs, expressed MRP and EF, and more than 80 per cent of the S suis serotype 9 strains produced an MRP+ protein, a high molecular weight variant of the 136 kDa MRP (Wisselink and others 2000) . In addition to serotype 2 strains, strains of serotypes 1, 1/2, 7, 9 and 14 are frequently isolated from diseased pigs. Further work is needed to determine whether MRP and EF are involved in the protection of pigs infected with strains of other serotypes producing MRP and/or EF.
_ ABSTRACT
Measurements of postoperative pain in cats THREE groups of six cats were subjected to either tenectomy or onychectomy, or to no surgical interference. Manual palpation and simple descriptive scales and visual analogue scales were then applied to assess and record the level of pain suffered by the cats, and the results were compared with measurements of the plasma concentrations of beta-endorphin and cortisol. Only the scores on the visual analogue scales and the responses of the cats to palpation differed significantly between the control group and the groups subjected to surgery; the physiological measurements failed to differentiate between them. 
